DI TOMMASO, VALERIA
 Distribuzione geografica
Continente #
NA - Nord America 1.056
EU - Europa 879
AS - Asia 540
Continente sconosciuto - Info sul continente non disponibili 4
Totale 2.479
Nazione #
US - Stati Uniti d'America 1.054
CN - Cina 282
UA - Ucraina 171
IE - Irlanda 164
TR - Turchia 123
GB - Regno Unito 113
SE - Svezia 100
IT - Italia 94
SG - Singapore 91
DE - Germania 76
FR - Francia 76
FI - Finlandia 48
IN - India 35
RU - Federazione Russa 25
CZ - Repubblica Ceca 6
EU - Europa 4
IR - Iran 4
BE - Belgio 3
KR - Corea 3
CA - Canada 2
GR - Grecia 2
DK - Danimarca 1
IL - Israele 1
PH - Filippine 1
Totale 2.479
Città #
Jacksonville 234
Chandler 205
Dublin 164
Southend 106
Nanjing 83
Princeton 80
Singapore 75
Ashburn 74
Beijing 65
Izmir 64
New York 42
Cambridge 39
Dearborn 37
Nanchang 28
Altamura 27
Wilmington 25
Santa Clara 23
Shenyang 16
Los Angeles 15
Norwalk 15
Washington 14
Grevenbroich 12
Tianjin 12
Ann Arbor 11
Jinan 10
Kunming 10
Helsinki 9
Torino 8
Guangzhou 7
Hebei 7
Jiaxing 7
Lanzhou 7
Campobasso 6
Chieti 6
Falls Church 6
Hangzhou 6
Leawood 6
Boardman 5
Brno 5
Changsha 5
Monmouth Junction 5
Ardabil 4
Bologna 4
Changchun 4
Montesilvano Marina 4
San Mateo 4
Augusta 3
Borgomanero 3
Brussels 3
Ningbo 3
San Vito Chietino 3
Taizhou 3
Teramo 3
Woodbridge 3
Zhengzhou 3
Hanover 2
Mumbai 2
Munich 2
Orange 2
Palermo 2
Palo Alto 2
Shanghai 2
Tappahannock 2
Aachen 1
Andover 1
Ascoli Piceno 1
Centrale 1
Chengdu 1
Domusnovas 1
Duncan 1
Espoo 1
Frankfurt am Main 1
Hyderabad 1
London 1
Manila 1
Meitingen 1
Monte di Procida 1
Montesilvano 1
Moscow 1
Mountain View 1
Nürnberg 1
Olomouc 1
Ottawa 1
Phoenix 1
Quanzhou 1
Redmond 1
Rome 1
San Salvo 1
Stanford 1
Toronto 1
Walnut 1
Totale 1.672
Nome #
Metabolomics analysis of cerebrospinal fluid reveals a distintive biochemical alteration associated with multiple sclerosis. 91
The Kurtzke EDSS rank stability increases 4 years after the onset of multiple sclerosis: results from the MSBase Registry. 88
Increasing age at disability milestones among MS patients in the MSBase Registry 85
Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone 79
Convulsive status epilepticus due to new encephalic demyelinating lesions in multiple sclerosis 78
Nail loss after teriflunomide treatment: a new potential adverse event 74
Effect of the disclosure of MS diagnosis on anxiety, mood and quality of life of patients: a prospective study 74
Anti-JCV serostatus, index value and clinical features in patients affected by multiple sclerosis. 73
Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome. 72
Breastfeeding is not related to postpartum relapses in multiple sclerosis. 71
An information aid for newly diagnosed multiple sclerosis patients improves disease knowledge and satisfaction with care. 71
Development and validation of a patient self-assessed questionnaire on satisfaction with communication of the multiple sclerosis diagnosis. 70
Patient adherence to and tolerability of self-administered interferon beta-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study 69
Natalizumab treatment in multiple sclerosis patients: a multicenter experience in clinical practice in Italy. 69
Neuropsychological testing and quantitative electroencephalography: a search of neurophysiological markers of cognitive decline in multiple sclerosis 66
Natalizumab-associated PML-IRIS: the Chieti experience. 66
JCV-Ab serostatus in MS patients treated with Natalizumab 65
Prevalence of JC virus antibodies in human serum and seroconversion rate with first-generation and second generation ELISA: the novel assay improves specificity andsensitivity to detect anti-JC virus antibodies 65
Treatment discontinuation issues in fingolimod treated patients: the Chieti experience. 64
Atypical presentation of Cadasil a diagnostic challenge 64
A difficult pediatric case: ADEM evolving in multiple sclerosis complicated by progressive multifocal leukoencephalopathy after Natalizumab treatment. 63
Multiphasic Adem or Multiple Sclerosis? Treatement implications. 63
Epidural analgesia and caesarean delivery are not associated with post-partum relapses and disability in MS. 63
Pregnancy and fetal outcomes after Glatiramer acetate exposure in patients with Multiple Sclerosis 60
Tumor necrosis factor α blockade therapy in a case of resistant primary angiitis of the central nervous system 59
Intramedullary Spinal Cord Glioblastoma: An Uncommon Diagnosis 58
Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study 57
Progressive multifocal leukoencephalopathy associated with natalizumab in paediatric multiple sclerosis 57
Neuropsychological testing and event-related potentials: markers of cognitive impairment in patients with multiple sclerosis 57
Epidural analgesia and caesarean delivery are not associated with post-partum relapses and disability in MS 57
Pregnancy outcomes and disease activity after exposure to natalizumab in patients with multiple sclerosis 56
Pregnancy outcomes and disease activity after exposure to natalizumab in patients with multiple sclerosis 56
Increased risk of disability progression after pregnancy in MS patients with active disease 53
Predictors of post-partum relapses and disability progression in Multiple Sclerosis 51
Pregnancy does not prevent disease re-activation after natalizumab suspension in patients with multiple sclerosis 48
Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs 47
Spinal cord injury in a patient with multiple sclerosis (MS) with secondary hydromyelia 46
Pregnancy and fetal outcomes after interferon-β exposure in multiple sclerosis 45
Stratify-2 Test in the clinical practice: results from a large multicentric italian database 45
Totale 2.495
Categoria #
all - tutte 9.969
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.969


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020271 0 0 0 0 0 33 62 52 9 43 71 1
2020/2021185 38 2 40 0 1 42 0 0 18 11 30 3
2021/2022153 0 3 6 29 6 5 11 13 8 5 24 43
2022/2023512 40 88 26 38 67 104 32 26 61 8 13 9
2023/2024320 15 21 24 11 30 144 40 0 1 7 3 24
2024/2025186 42 64 64 3 7 6 0 0 0 0 0 0
Totale 2.495